106 related articles for article (PubMed ID: 23396856)
1. Frequency of amino acid changes associated with resistance to attachment inhibitor BMS-626529 in R5- and X4-tropic HIV-1 subtype B.
Soulié C; Lambert-Niclot S; Fofana DB; Fourati S; Ait-Arkoub Z; Sayon S; Simon A; Katlama C; Calvez V; Marcelin AG
J Antimicrob Chemother; 2013 Jun; 68(6):1243-5. PubMed ID: 23396856
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of subtype-related polymorphisms associated with in vitro resistance to attachment inhibitor BMS-626529 in HIV-1 'non-B'-infected patients.
Charpentier C; Larrouy L; Visseaux B; Landman R; Levittas M; Storto A; Damond F; Yazdanpanah Y; Yeni P; Brun-Vézinet F; Descamps D
J Antimicrob Chemother; 2012 Jun; 67(6):1459-61. PubMed ID: 22382470
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.
Svicher V; Balestra E; Cento V; Sarmati L; Dori L; Vandenbroucke I; D'Arrigo R; Buonomini AR; Van Marck H; Surdo M; Saccomandi P; Mostmans W; Aerssens J; Aquaro S; Stuyver LJ; Andreoni M; Ceccherini-Silberstein F; Perno CF
Antiviral Res; 2011 Apr; 90(1):42-53. PubMed ID: 21349294
[TBL] [Abstract][Full Text] [Related]
4. Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068.
Zhou N; Nowicka-Sans B; McAuliffe B; Ray N; Eggers B; Fang H; Fan L; Healy M; Langley DR; Hwang C; Lataillade M; Hanna GJ; Krystal M
J Antimicrob Chemother; 2014 Mar; 69(3):573-81. PubMed ID: 24128669
[TBL] [Abstract][Full Text] [Related]
5. Genetic barrier for attachment inhibitor BMS-626529 resistance in HIV-1 B and non-B subtypes.
Fofana DB; Charpentier C; Maïga AI; Lambert-Niclot S; Sayon S; Désiré N; Simon A; Yazdanpanah Y; Katlama C; Descamps D; Calvez V; Marcelin AG; Soulié C
J Antimicrob Chemother; 2015 Jan; 70(1):130-5. PubMed ID: 25270328
[TBL] [Abstract][Full Text] [Related]
6. Primary resistance to maraviroc in a large set of R5-V3 viral sequences from HIV-1-infected patients.
Seclén E; González Mdel M; Lapaz M; Rodríguez C; del Romero J; Aguilera A; de Mendoza C; Soriano V; Poveda E
J Antimicrob Chemother; 2010 Dec; 65(12):2502-4. PubMed ID: 20940179
[TBL] [Abstract][Full Text] [Related]
7. Prediction of virological response and assessment of resistance emergence to the HIV-1 attachment inhibitor BMS-626529 during 8-day monotherapy with its prodrug BMS-663068.
Ray N; Hwang C; Healy MD; Whitcomb J; Lataillade M; Wind-Rotolo M; Krystal M; Hanna GJ
J Acquir Immune Defic Syndr; 2013 Sep; 64(1):7-15. PubMed ID: 23614999
[TBL] [Abstract][Full Text] [Related]
8. Primary resistance of CCR5-tropic HIV-1 to maraviroc cannot be predicted by the V3 sequence.
Delobel P; Cazabat M; Saliou A; Loiseau C; Coassin L; Raymond S; Requena M; Marchou B; Massip P; Izopet J
J Antimicrob Chemother; 2013 Nov; 68(11):2506-14. PubMed ID: 23794603
[TBL] [Abstract][Full Text] [Related]
9. Co-receptor switch during HAART is independent of virological success.
Saracino A; Monno L; Cibelli DC; Punzi G; Brindicci G; Ladisa N; Tartaglia A; Lagioia A; Angarano G
J Med Virol; 2009 Dec; 81(12):2036-44. PubMed ID: 19856465
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of X4 tropic viruses in patients recently infected with HIV-1 and lack of association with transmission of drug resistance.
de Mendoza C; Rodriguez C; García F; Eiros JM; Ruíz L; Caballero E; Aguilera A; Leiva P; Colomina J; Gutierrez F; del Romero J; Aguero J; Soriano V;
J Antimicrob Chemother; 2007 Apr; 59(4):698-704. PubMed ID: 17327295
[TBL] [Abstract][Full Text] [Related]
11. In vivo patterns of resistance to the HIV attachment inhibitor BMS-488043.
Zhou N; Nowicka-Sans B; Zhang S; Fan L; Fang J; Fang H; Gong YF; Eggers B; Langley DR; Wang T; Kadow J; Grasela D; Hanna GJ; Alexander L; Colonno R; Krystal M; Lin PF
Antimicrob Agents Chemother; 2011 Feb; 55(2):729-37. PubMed ID: 21078948
[TBL] [Abstract][Full Text] [Related]
12. Impact of natural polymorphisms of HIV-1 non-group M on genotypic susceptibility to the attachment inhibitor fostemsavir.
Alessandri-Gradt E; Charpentier C; Leoz M; Mourez T; Descamps D; Plantier JC
J Antimicrob Chemother; 2018 Oct; 73(10):2716-2720. PubMed ID: 30032194
[TBL] [Abstract][Full Text] [Related]
13. Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5.
Ogert RA; Hou Y; Ba L; Wojcik L; Qiu P; Murgolo N; Duca J; Dunkle LM; Ralston R; Howe JA
Virology; 2010 Apr; 400(1):145-55. PubMed ID: 20172579
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 co-receptor usage based on V3 loop sequence analysis: preferential suppression of CXCR4 virus post HAART?
Jiao Y; Wang P; Zhang H; Zhang T; Zhang Y; Zhu H; Wu H
Immunol Invest; 2011; 40(6):597-613. PubMed ID: 21513481
[TBL] [Abstract][Full Text] [Related]
15. Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events.
Ho HT; Fan L; Nowicka-Sans B; McAuliffe B; Li CB; Yamanaka G; Zhou N; Fang H; Dicker I; Dalterio R; Gong YF; Wang T; Yin Z; Ueda Y; Matiskella J; Kadow J; Clapham P; Robinson J; Colonno R; Lin PF
J Virol; 2006 Apr; 80(8):4017-25. PubMed ID: 16571818
[TBL] [Abstract][Full Text] [Related]
16. Subtype analysis and mutations to antiviral drugs in HIV-1-infected patients from Mozambique before initiation of antiretroviral therapy: results from the DREAM programme.
Bellocchi MC; Forbici F; Palombi L; Gori C; Coelho E; Svicher V; D'Arrigo R; Emberti-Gialloreti L; Ceffa S; Erba F; Marazzi MC; Silberstein FC; Perno CF
J Med Virol; 2005 Aug; 76(4):452-8. PubMed ID: 15977236
[TBL] [Abstract][Full Text] [Related]
17. Naturally occurring resistance mutations to HIV-1 entry inhibitors in subtypes B, C, and CRF31_BC.
Araújo LA; Junqueira DM; de Medeiros RM; Matte MC; Almeida SE
J Clin Virol; 2012 May; 54(1):6-10. PubMed ID: 22336085
[TBL] [Abstract][Full Text] [Related]
18. Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155.
Madani N; Perdigoto AL; Srinivasan K; Cox JM; Chruma JJ; LaLonde J; Head M; Smith AB; Sodroski JG
J Virol; 2004 Apr; 78(7):3742-52. PubMed ID: 15016894
[TBL] [Abstract][Full Text] [Related]
19. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).
Marozsan AJ; Kuhmann SE; Morgan T; Herrera C; Rivera-Troche E; Xu S; Baroudy BM; Strizki J; Moore JP
Virology; 2005 Jul; 338(1):182-99. PubMed ID: 15935415
[TBL] [Abstract][Full Text] [Related]
20. A combination of polymorphic mutations in V3 loop of HIV-1 gp120 can confer noncompetitive resistance to maraviroc.
Yuan Y; Maeda Y; Terasawa H; Monde K; Harada S; Yusa K
Virology; 2011 May; 413(2):293-9. PubMed ID: 21440278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
